Optimized Transduction of Canine Paediatric CD34+ Cells Using an MSCV-based Bicistronic Vector
Steven E. Suter(North Carolina State University), Paula S. Henthorn(University of Pennsylvania), Mark E. Haskins(University of Pennsylvania), Peter A. McSweeney(Mesoblast (United States)), P. J. Felsburg, Terry A. Gouthro(University of Pennsylvania), Richard A. Nash(Colorado Blood Cancer Institute)
Cited by 9
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k